Clinical Trial: 10-year Follow-up After a Single Dose Acellular Pertussis Vaccination

U.S., Feb. 1 -- ClinicalTrials.gov registry received information related to the study (NCT06803524) titled '10-year Follow-up After a Single Dose Acellular Pertussis Vaccination' on Jan. 27.

Brief Summary: This is a phase IV, open-label, non-randomized study to demonstrate superior immunogenicity and safety of a second booster dose of Pertagen(R) as compared to Adacel(R) at 10 years after the first booster vaccination and to evaluate the long-term persistence of specific antibodies induced by BioNet's recombinant aP (Pertagen(R)) and TdaP (Boostagen(R)) vaccines and a chemically-detoxified Tdap vaccine (Adacel(R)) at 10 years after the first booster in participants who were vaccinated in the phase II/III trial (Protocol No. TDA202).

Study...